Fycompa (perampanel)
- Region
- 🇪🇺 EU
- Active substance
- perampanel
- Company
- Eisai GmbH
- Status
- Authorised
- Therapeutic area
- Epilepsies, Partial
- CHMP opinion
- Thu 24 May 2012
- EU approval
- Mon 23 Jul 2012
- Application
- EMEA/H/C/002434
- ATC
- N03AX22
- Official record
- www.ema.europa.eu
Indication
Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.
Regulatory milestones
No milestones recorded in the last year.
Follow Fycompa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.